Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Dr Landgren on the Rationale for Assessing Daratumumab Plus KRd in Newly Diagnosed Myeloma

August 29th 2025

C. Ola Landgren, MD, PhD, discusses the use of MRD as an early end point in a study evaluating daratumumab plus KRd in newly diagnosed multiple myeloma.

Dr Khan on the Development of Second-Generation BTK Inhibitors in CLL

August 29th 2025

Cyrus M. Khan, MD, detailed the development of second-generation BTK inhibitors and how they compare with first-generation BTK inhibitors in CLL.

FDA’s Push for Faster Drug Reviews Intersects With Policy Shifts on EU-Imposed Tariffs

August 29th 2025

As the FDA aims to reduce drug review times, the 15% tariff rate imposed on pharmaceuticals from Europe could affect drug access in the oncology space.

Dr D’Amato on the Rationale for Studying Olaparib/Temozolomide in Leiomyosarcoma

August 28th 2025

Gina Z. D’Amato, MD, discusses the rationale for investigating olaparib plus temozolomide in previously treated advanced uterine leiomyosarcoma.

Dr Vose on the Development of Epcoritamab in Relapsed/Refractory DLBCL

August 28th 2025

Julie M. Vose, MD, MBA, details the rationale for evaluating epcoritamab for the treatment of patients with relapsed/refractory DLBCL with limited options.

Dr Tan on the Management of ADC-Related Toxicities in Breast Cancer

August 28th 2025

Antoinette Tan, MD, MHS, discusses the safety profiles of ADCs and ADC selection considerations for breast cancer.

Dr Qin on the Design of the HARMONY Trial of Niraparib-Based Therapy in mHSPC

August 28th 2025

Qian (Janie) Qin, MD, discusses the unique design of the phase 2 HARMONY trial of first-line niraparib plus abiraterone acetate and prednisone in mHSPC.

Annamycin Plus Cytarabine Drive Potential OS Benefit in Acute Myeloid Leukemia

August 28th 2025

Annamycin plus cytarabine produced a potential overall survival benefit in acute myeloid leukemia.

FDA to Review Gedatolisib NDA in HR+/HER2–, PIK3CA Wild-Type Advanced Breast Cancer

August 28th 2025

The FDA has agreed to review an NDA submission for gedatolisib in hormone receptor–positive/HER2-negative, PIK3CA wild-type advanced breast cancer.

D3S-001 Receives FDA Breakthrough Therapy, Orphan Drug Designations in Select KRAS G12C-Mutant Solid Tumors

August 28th 2025

D3S-001 has received FDA breakthrough therapy and orphan drug designations in KRAS G12C-mutated NSCLC and CRC, respectively.

De-Escalated Surgical Strategies for Locoregional Breast Cancer Expand to Broader Populations

August 28th 2025

Tari A. King, MD, FACS, FSSO, FASCO, discusses locoregional breast cancer management strategies and avoiding lymph node dissection in select patients.

Daratumumab Plus KRd Offers a New Standard of Care in Newly Diagnosed Multiple Myeloma

August 27th 2025

C. Ola Landgren, MD, PhD, discusses the feasibility of daratumumab plus KRd as a standard of care for the management of newly diagnosed multiple myeloma.

Dr Morgans on the Rationale for Evaluating Darolutamide Plus ADT in High-Risk Biochemical Recurrence of Prostate Cancer

August 27th 2025

Alicia Morgans, MD, MPH, discusses the background of darolutamide plus ADT in patients with prostate cancer with high-risk biochemical recurrence.

Dr Nathan on the Rationale for Evaluating Roginolisib in Advanced Ocular or Uveal Melanoma

August 27th 2025

Paul Nathan, MBBS, PhD, MRCP, details the rationale for evaluating roginolisib in patients with advanced or metastatic ocular or uveal melanoma.

European Commission Greenlights UM171 Cell Therapy for Hematologic Malignancies

August 27th 2025

UM171 cell therapy has earned European Commission approval for the treatment of patients with hematologic malignancies requiring HSCT.

Researchers Build Real-World External Control Arm to Accelerate HER2+ Breast Cancer Drug Development

August 26th 2025

Jessica Paulus, ScD, discusses the incorporation of an external control arm into the analysis of a phase 2 trial in HER2-positive breast cancer.

FDA Grants Fast Track Designation to Stenoparib for Advanced Ovarian Cancer

August 26th 2025

Stenoparib receives FDA fast track designation for the treatment of patients with advanced ovarian cancer.

Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer

August 26th 2025

The FDA has granted breakthrough therapy designation to rinatabart sesutecan for the treatment of patients with advanced or recurrent endometrial cancer who have disease progression on or following standard-of-care therapy.

4 Ways Oncologists Use Social Media to Debunk Myths and Dispel Misinformation

August 26th 2025

Eric K. Singhi, MD, and Shruti Patel, MD, discuss how they extend beyond the walls of their clinic to provide accurate cancer updates on social media.

Paulus on Research With a Real-World External Control Arm in HER2+ Breast Cancer

August 25th 2025

Jessica Paulus, ScD, discusses the development of a real-world control arm to inform the utility of findings from a trial in HER2-positive breast cancer.